BCIQ Profiles

Company Profile Report

Ultragenyx's rhGUS meets Phase III endpoint

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said rhGUS (UX003) met the primary endpoint in a Phase III study to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) by significantly reducing urinary excretion of glycosaminoglycan (GAG) dermatan sulfate

Read the full 340 word article

How to gain access

Continue reading with a
two-week free trial.